| abstract |
The invention provides for the use of an effective amount of at least one cannabinoid selected from the group consisting of HU-210 and Tetrahydrocannabinol (THC) for the manufacture of a pharmaceutical composition for alleviating neuronal damage due to hyperglycemia, or for treating neuronal damage in a diabetic subject, wherein HU-210 is the (+)-1,1-dimethylheptyl analog of 7-hydroxy-delta-6- tetrahydrocannabinol of the formula (I). |